ライフサイエンスコーパス: -precipitated withdrawal

1 splay both abstinence-induced and antagonist-precipitated withdrawal signs, indicative of the develop

2 avior during both spontaneous and antagonist-precipitated withdrawal was measured by potentiation of

3 regions with chronic morphine and antagonist-precipitated withdrawal.

4 of amino acids before and during antagonist-precipitated withdrawal in unanesthetized rats was exami

5 utonomic manifestations of opioid antagonist-precipitated withdrawal in morphine-tolerant rats.

6 ce, as indicated by a less severe antagonist-precipitated withdrawal syndrome.

7 us (LC) during nor-binaltorphimine (nor-BNI)-precipitated withdrawal from butorphanol, (5alpha,7alpha

8 ndicated increased concern for buprenorphine-precipitated withdrawal (PW); however, some observationa

9 ar rapid blocking of naloxone (10 microg/kg)-precipitated withdrawal hyperalgesia and unmasking of pr

10 noted after nor-BNI (48 nmol/50 microl, LC)-precipitated withdrawal in rats that had been intracereb

11 Mecamylamine-precipitated withdrawal significantly increased activity

12 Naloxone-precipitated withdrawal in morphine-dependent mice or op

13 during acute morphine exposure and naloxone-precipitated withdrawal in two regions associated with t

14 Chronic morphine exposure and naloxone-precipitated withdrawal increase activity of spinal MMP-

15 ly promotes analgesic tolerance and naloxone-precipitated withdrawal, whereas downregulation of G9a i

16 o induce dependence, as revealed by naloxone-precipitated withdrawal in saline or mismatch-pretreated

17 morphine dependence as assessed by naloxone-precipitated withdrawal jumping.

18 ependence liability as indicated by naloxone-precipitated withdrawal studies.

19 morphine action was interrupted by naloxone-precipitated withdrawal.

20 orphine dependence (i.e., decreased naloxone-precipitated withdrawal jumping).

21 Low-dose naloxone-precipitated withdrawal hyperalgesia is a reliable indic

22 s.c. naloxone (10 mg/kg) to induce naloxone-precipitated withdrawal syndrome on the final day of the

23 In fentanyl-dependent mice, naloxone-precipitated withdrawal increased spontaneous neural act

24 We studied how repeated cycles of naloxone-precipitated withdrawal from otherwise continuous opioid

25 Here, we show that somatic signs of naloxone-precipitated withdrawal were associated with increased P

26 markedly attenuates development of naloxone-precipitated withdrawal-jumping in physical dependence a

27 us or interrupted by daily bouts of naloxone-precipitated withdrawal.

28 an L-type Ca2+ channel blocker, on naloxone-precipitated withdrawal and elevations of glutamate leve

29 ns of the PKA inhibitor Rp-cAMPS on naloxone-precipitated withdrawal from morphine was examined.

30 ke effect and hyperalgesia, reduced naloxone-precipitated withdrawal signs, and normalized the increa

31 as evaluated by quantifying/scoring naloxone-precipitated withdrawal signs.

32 the maintenance of dependence until naloxone-precipitated withdrawal.

33 hen dependence was maintained until naloxone-precipitated withdrawal.

34 hrough pairings of one chamber with naloxone-precipitated withdrawal and the other chamber with salin

35 tly, stimuli repeatedly paired with naloxone-precipitated withdrawal provoked heroin consumption and

36 dase (beta-gal) expression during naltrexone-precipitated withdrawal.

37 attenuating development of tolerance and NLX-precipitated withdrawal-jumping during chronic cotreatme

38 o overcoming established dependence, the NLX-precipitated withdrawal phenomena in rats that had recei

39 ct to the development of dependence, the NLX-precipitated withdrawal phenomena were reduced in rats t

40 940 also produced hypothermia and rimonabant-precipitated withdrawal in WT, but not CB1KO, mice.

41 40 did not produce hypothermia or rimonabant-precipitated withdrawal in CB1KO mice.